Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Capital Expenditures (2016 - 2026)

Standard Biotools has reported Capital Expenditures over the past 16 years, most recently at $8.2 million for Q4 2025.

  • Quarterly Capital Expenditures rose 358.56% to $8.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2025, up 357.72% year-over-year, with the annual reading at $8.3 million for FY2025, 357.72% up from the prior year.
  • Capital Expenditures was $8.2 million for Q4 2025 at Standard Biotools, up from -$6.8 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $12.8 million in Q3 2021 and troughed at -$6.8 million in Q3 2025.
  • The 5-year median for Capital Expenditures is $921500.0 (2022), against an average of $2.3 million.
  • Year-over-year, Capital Expenditures skyrocketed 3676.11% in 2021 and then tumbled 464.64% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $500000.0 in 2021, then soared by 51.0% to $755000.0 in 2022, then tumbled by 464.64% to -$2.8 million in 2023, then decreased by 14.75% to -$3.2 million in 2024, then soared by 358.56% to $8.2 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Capital Expenditures are $8.2 million (Q4 2025), -$6.8 million (Q3 2025), and $1.9 million (Q2 2025).